PALI - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

Palisade Bio received FDA clearance of its IND for PALI-2108, enabling a Phase 2 Crohn’s study (~60 patients), with first dosing expected in Q1 2027 and primary Week 12 endoscopic response readout targeted for Q1 2028.Material DetailsContext by AI AnalystThis is an early-to-mid stage development st…